在初级晚期卵巢癌中使用多斯塔利马布和尼拉帕里布
A-C Hardy-Bessard1, E Pujade-Lauraine2, R G Moore3
1Centre Armoricain d'Oncologie, CARIO-HPCA and GINECO, Plérin, France.
概括
在化疗和尼拉帕里布维护中添加德巴利利马布,在晚期卵巢癌中改善了无进展的生存率. 然而,这种组合在FIRST/ENGOT-OV44试验中没有显著影响整体生存率.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 免疫治疗是一种免疫疗法.
背景情况:
- 晚期卵巢癌 (aOC) 治疗策略正在发展.
- 结合免疫疗法与多 (ADP-ribose) 聚合酶抑制剂 (PARPis) 的结合显示出有前途.
- 在FIRST/ENGOT-OV44试验中,研究了aOC的新疗法组合.
研究的目的:
- 评估添加德巴利利马布到一线化疗和aOC中尼拉帕里布维护的疗效和安全性.
- 为了比较治疗手臂之间的无进展生存 (PFS) 和整体生存 (OS).
- 评估免疫治疗与PARPi结合在aOC管理中的作用.
主要方法:
- 一个随机的,双盲的III期试验,涉及新诊断的III-IV期上皮卵巢癌患者.
- 患者接受了基于的化疗 (PBCT) 与安慰剂或达尔利马布,随后是尼拉帕里布维护±贝瓦西祖马布.
- 主要终点是研究人员评估的PFS;次要终点是OS.
主要成果:
- 随着多达利利马布的添加,观察到PFS的统计显著改善 (中位数为20.6个月与19.2个月;HR 0.85,P=0.0351).
- 总体存活率在两组之间没有统计学上显著的差异 (中位数为44.4个月与45.4个月;HR为1.01,P=0.9060).
- 观察到的毒性与使用的药物的已知安全性概况一致.
结论:
- 在一线PBCT和尼拉帕里布维护中添加达尔利马布,在晚期卵巢癌中提供了统计学上显著但临床上适度的PFS益处.
- 这种组合并没有显著改善整体存活率.
- 可能需要进一步的研究来优化免疫疗法和PARPi组合,以改善aOC的长期结果.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
597
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
597
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
817
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
817
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
606
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
606


